| Expression pattern: |
UP |
| Associated gene: |
IGF1 |
| Associated microRNA: |
miR-126-5p |
| Biological function: |
promotes paclitaxel resistance/chemoresistance in NSCLC |
| Molecular mechanism: |
Regulates the miR-126-5p/IGF1 axis (ceRNA-like regulation implied by predicted binding sites and anti-miRNA rescue). |
| Biological pathway or process: |
chemoresistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Clinical Sample Validation; Survival Analysis; ROC Analysis; Bioinformatics Analysis; Transfection; MTT; ELISA |
| Clinical significance: |
Serum hsa_circ_0005962 is increased in chemoresistant NSCLC patients, shows diagnostic utility (AUC-ROC 0.9014), and high expression is associated with shorter OS and is an independent prognostic predictor. |
| Description: |
hsa_circ_0005962 is up-regulated in NSCLC patient serum, especially in paclitaxel-chemoresistant cases, and higher levels correlate with advanced clinicopathological features and worse survival. Functionally, it promotes paclitaxel resistance in NSCLC cells by regulating the miR-126-5p/IGF1 axis and shows diagnostic/prognostic value (ROC and survival analyses). |
| Confidence score: |
0.7682 |